TVTX Q3 2024 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$63M+69.6% YoY

Gross Profit

$61M97.4% margin

Operating Income

-$56M-89.3% margin

Net Income

-$55M-87.1% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

+16.2%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$51M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$504M

Total Liabilities

$535M

Stockholders' Equity

-$30M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$63M	$37M	+69.6%
Gross Profit	$61M	$36M	+71.1%
Operating Income	-$56M	-$93M	+39.4%
Net Income	-$55M	$151M	-136.4%

Revenue Segments

Product

$61M97%

License

$2M3%